Treatments for Interventional Radiology
Centra Health is proud to announce the launch of Pluvicto™, an innovative treatment now available in our Nuclear Medicine department. Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) represents the cutting edge of theranostic care, combining precision diagnostics and targeted therapy to treat advanced prostate cancer.
What is Pluvicto™?
Pluvicto™ is a targeted radioligand therapy designed for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). It delivers a therapeutic dose of radiation directly to cancer cells, sparing surrounding healthy tissue. This breakthrough treatment provides new hope for patients who have exhausted conventional options.
Who is Eligible?
Pluvicto™ is designed for patients with mCRPC who have received androgen receptor pathway inhibition and taxane-based chemotherapy. Speak with your physician to determine if this treatment is right for you.
